Effect of long-term treatment with galantamine on weight of patients with Alzheimer's dementia

Journal of Nutrition, Health and Aging

Volumn 17, Issue 5, 2013, Pages 461-465

  Droogsma, E ^a   Van Asselt, D Z B ^a   Van Steijn, J H M ^a   Schuur, T ^a   Huinink, E J ^a  

^a MEDICAL CENTER LEEUWARDEN   (Netherlands)

Author keywords

Alzheimer disease; cholinesterase inhibitors; community dwelling; longitudinal study; weight loss

Indexed keywords

GALANTAMINE; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; BODY MASS; BODY WEIGHT; COGNITION; COMMUNITY LIVING; COMORBIDITY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL STATUS; PRIORITY JOURNAL; SOCIAL STATUS;

EID: 85027937179     PISSN: 12797707     EISSN: 17604788     Source Type: Journal    
DOI: 10.1007/s12603-012-0420-6     Document Type: Article

References (30)

1. Gillette-Guyonnet S, Nourhashemi F, Andrieu S, de Glisezinski I, Ousset PJ, Riviere D, et al Weight loss in Alzheimer disease (2000) Am J Clin Nutr 71(2):637-642
2. White H, Pieper C, Schmader K, Fillenbaum G. Weight change in Alzheimer's disease (1996) J Am Geriatr Soc 44(3):1232-1234
3. Faxen-Irving G, Basun H, Cederholm T. Nutritional and cognitive relationships and long-term mortality in patients with various dementia disorders (2005) Age Ageing 34(2):136-141
4. Gambassi G, Landi F, Lapane KL, Sqadari A, Mor V, Bernabei Rl. Predictors of mortality in patients with Alzheimer's disease living in nursing homes (1999) J Neurol Neurosurg Psychiatry 67(1):59-65
5. White H, Pieper C, Schmader K. The association of weight change in Alzheimer's disease with severity of disease and mortality: A longitudinal analysis (1998) J Am Geriatr Soc 46(10):1223-1227
6. Scneider LS. The future of cholinergic replacement therapy in Alzheimer's disease (2000) Curr Opin Investig Drugs 2(4):427-437
7. Massoud F, Gauthier S. Update on the pharmalogical treatment of Alzheimer's disease (2010) Current Neuropharmacology 8:69-80
8. Birks J. Cholinesterase inhibitors for Alzheimer's disease (2006) Cochrane Database Syst Rev CD005593
9. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-mont extension (2000) Neurology 54:2261-2268
10. Gillette-Guyonnet S, Cortes F, Cantet C, Vellas B. Long-term cholinergic treatment is not associated with greater risk of weight loss during Alzheimer's disease: data from the French Real. Fr Cohort (2005) J Nutr Health Aging 9(2):69-73
11. Gillette-Guyonnet S, Andrieu S, Cortes F, Nourhashemi F, Cantet C, Ousset PJ, et al. Outcome of Alzheimer's Disease: Potential Impact of Cholinesterase Inhibitors (2006) Journal of Gerontology 61A(5):516-520
12. Lockhart IA, Mitchell SA, Kelly S. Safety and Tolerability of donepezil, rivastigmine and galantamine for patients with Alzeimer's disease: systematic review of the' realworld' evidence (2009) Dement Geriatr Cogn Disord 28:389-403
13. Gillette-Guyonnet S, Abellan van Kan G, Alix E, Andrieu S, Belmin J, Berrut G, et al. IANA (International Academy on Nutrition and Aging) Expert group: weight loss and Alzheimer's disease (2007) J Nutr Health Aging 11(1):38-48
14. Praisoody A. Caution when prescribing cholinesterase inhibitors (2012) J Am Geriatr Soc 60(4):805-806
15. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD (2000) Neurology 54:2269-2276
16. Guérin O, Andrieu S, Schneider SM, Milano M, Boulahssass R, Brocker P, et al. Different modes of weight loss in Alzheimer disease: a prospective study of 395 patients (2005) Am J Clin Nutr 82:435-441
17. Guérin O, Andrieu S, Schneider SM, Cortes F, Cantet C, Gillette-Guyonnet S, et al. Characteristics of Alzheimer's disease patients with a rapid weight loss during a sixyear follow-up (2009) Clinical Nutrition 28:141-146
18. Gardette V, Andrieu S, Lapeyre-Mestre M, Coley N, Cantet C, Ousset PJ, et al. Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease. A 2-year prospective, mulitcentre, cohort study (2001) CNS Drugs 24(5):431-442
19. Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease (2002) J Neurol Neurosurg Psychiatry 72:310-314
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease (1984) Neurology 34:189-198
21. Salvi F, Miller MD, Towers A, Grilli A, Morichi V, Giorgi R, et al. Guidelines for Scoring the Modified Cumulative Illness Rating Scale (CIRS) (2008) Pittsburgh, PA: University of Pittsburgh
22. Salvi F, Miller MD, Grilli A, Giorgi R, Towers AL, Morichi V, et al. A Manual of Guidelines to Score the Modified Cumulative Illness Rating Scale and Its Validation in Acute Hospitalized Elderly Patients (2008) J Am Geriatr Soc 56:1926-1931
23. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician (1975) J Pyschiatr Res 12:189-198
24. Shulman KI, Gold DP, Cohen CA, Zucchero CA. Clock-drawing and dementia in the community: a longitudinal study (1993) Int J Geriatr Psychiatry 8:487-496
25. Zeger SL, Liang KY. Longitudinal Data Analysis for Discrete and Continuous Outcomes (1986) Biometrics 42:121-130
26. Belmin J, and the members of the expert panel and organisation committee. Practical guidelines for the diagnosis and management of weight loss in Alzheimer's disease: a consensus from appropriateness ratings of a large expert panel (2007) J Nutr Health Aging 11(1):33-37
27. Mohs R, Schmeidler J, Aryan M. Longitudinal studies of cognitive, functional and behavioural change in patients with Alzheimer's disease (2000) Statist Med 19:1401-1409
28. Bilotta C, Bergamaschini L, Arienti R, Spreafico S, Vergani C. Caregiver burden as a short-term predictor of weight loss in older outpatients suffering from mild to moderate Alzheimer's disease; a three months follow-up study (2010) Aging & Mental Health 4(4):481-488
29. National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. Review of NICE technology appraisal guidance 111 (2011) www.nice.org.uk/guidance/TA217
30. White H, Pieper C, Schmader K. The association of weight change in Alzheimer's disease with severity of disease and mortality: a longitudinal analysis (1998) J Am Geriatr Soc 46(10):1223-1227